As reported by the Wall Street Journal, Eisai, the Tokyo-based pharmaceutical company, has been given another weapon by the FDA against competition from generics companies for its Alzheimer’s drug Aricept – a higher dosage form of the drug has now been approved by the agency.
According to recent studies, patients using this higher dosage (23-mg) drug got better results than those using the lower dose. So, even though the 10-mg version is due to be released in November, Eisai is hopeful that the approval of the higher dosage drug will keep the generic lower dosage version from slashing sales.
Meanwhile, Eisai is reportedly planning to move their manufacturing to India with the main aim of lowering overall production costs of Aricept. This will enable the company to compete with the generics makers.
Are you looking for your next position in the pharmaceutical industry? Click here to search our current pharmaceutical jobs now.